Basaglar: A Hypersensitivity Reaction.
作者信息
Gavioli Elizabeth M, Fazylov Roman, Sardo Gulmira
机构信息
Kingsbrook Jewish Medical Center, Brooklyn, NY.
Touro College of Pharmacy, New York, NY.
出版信息
Clin Diabetes. 2018 Apr;36(2):205-207. doi: 10.2337/cd17-0051.
Abstract
摘要
相似文献
1
Basaglar: A Hypersensitivity Reaction.百畅泽：一种超敏反应。
Clin Diabetes. 2018 Apr;36(2):205-207. doi: 10.2337/cd17-0051.
2
Basaglar, an Insulin 'Follow On,' Prepares To Do Battle With Lantus.基础胰岛素类似物Basaglar准备与来得时展开竞争。
Manag Care. 2017 Apr;26(4):12-14.
3
Glargine U-100 (Basaglar®): A Follow-On Insulin.
Home Healthc Now. 2016 Jun;34(6):336-7. doi: 10.1097/NHH.0000000000000414.
4
Basaglar.百畅泽（胰岛素甘精注射液的商品名）
Clin Diabetes. 2017 Jul;35(3):181. doi: 10.2337/cd017-0025.
5
Similar Efficacy and Safety of Basaglar and Lantus in Patients with Type 2 Diabetes in Age Groups (< 65 Years, ≥ 65 Years): A Post Hoc Analysis from the ELEMENT-2 Study.在2型糖尿病患者中（年龄组<65岁、≥65岁），Basaglar和来得时的疗效与安全性相似：来自ELEMENT-2研究的事后分析
Diabetes Ther. 2018 Apr;9(2):827-837. doi: 10.1007/s13300-018-0405-5. Epub 2018 Mar 14.
6
Another insulin glargine (Basaglar) for diabetes.
Med Lett Drugs Ther. 2017 Jan 2;59(1511):3-4.
7
Nonclinical pharmacology and toxicology of the first biosimilar insulin glargine drug product (BASAGLAR/ABASAGLAR) approved in the European Union.欧盟批准的首个生物类似药甘精胰岛素产品（BASAGLAR/ABASAGLAR）的非临床药理学与毒理学
Regul Toxicol Pharmacol. 2017 Aug;88:56-65. doi: 10.1016/j.yrtph.2017.05.013. Epub 2017 May 17.
8
Interaction among IgE-mediated hypersensitivity reaction, PCA reaction and delayed hypersensitivity reaction (at local skin sites of monkeys).IgE介导的超敏反应、被动皮肤过敏反应和迟发型超敏反应之间的相互作用（在猴的局部皮肤部位）。
Int Arch Allergy Appl Immunol. 1979;59(4):373-82. doi: 10.1159/000232284.
9
Expanded table: some available insulins for type 2 diabetes.
Med Lett Drugs Ther. 2019 May 6;61(1571):e73-e77.
10
Insulins for type 2 diabetes.用于2型糖尿病的胰岛素。
Med Lett Drugs Ther. 2019 May 6;61(1571):65-68.
本文引用的文献
1
Awareness, Knowledge, and Perceptions of Biosimilars Among Specialty Physicians.专科医生对生物类似药的认知、了解及看法。
Adv Ther. 2017 Jan;33(12):2160-2172. doi: 10.1007/s12325-016-0431-5. Epub 2016 Oct 31.
2
Efficacy and safety of LY2963016 insulin glargine compared with insulin glargine (Lantus®) in patients with type 1 diabetes in a randomized controlled trial: the ELEMENT 1 study.在一项随机对照试验中，LY2963016 胰岛素甘精与胰岛素甘精（来得时）治疗 1 型糖尿病患者的疗效和安全性比较：ELEMENT 1 研究。
Diabetes Obes Metab. 2015 Aug;17(8):726-33. doi: 10.1111/dom.12496. Epub 2015 Jun 23.
3
Similar efficacy and safety of LY2963016 insulin glargine and insulin glargine (Lantus®) in patients with type 2 diabetes who were insulin-naïve or previously treated with insulin glargine: a randomized, double-blind controlled trial (the ELEMENT 2 study).LY2963016 胰岛素甘精和胰岛素甘精（来得时®）在初治或既往使用胰岛素甘精的 2 型糖尿病患者中的疗效和安全性相似：一项随机、双盲对照试验（ELEMENT 2 研究）。
Diabetes Obes Metab. 2015 Aug;17(8):734-41. doi: 10.1111/dom.12482. Epub 2015 May 31.
4
Hypersensitivity reaction to a biosimilar insulin glargine.对生物类似物甘精胰岛素的超敏反应。
J Diabetes. 2015 Mar;7(2):155-7. doi: 10.1111/1753-0407.12241. Epub 2015 Jan 7.
5
Biosimilar insulins: how similar is similar?生物类似物胰岛素：相似度究竟多高？
J Diabetes Sci Technol. 2011 May 1;5(3):741-54. doi: 10.1177/193229681100500329.
Zotero 插件